A promising clinical trial utilizing gold-silica core-shell nanostructures coated with polyethylene glycol (PEG) has been reported for near-infrared (NIR) photothermal therapy (PTT) of prostate cancer. The next critical step for PTT is the visualization of therapeutically relevant nanoshell (NS) concentrations at the tumor site. Here we report the synthesis of PEGylated Gd 2 O 3 -mesoporous silica/gold core/shell NSs (Gd 2 O 3 -MS NSs) with NIR photothermal properties that also supply sufficient MRI contrast to be visualized at therapeutic doses (≥10 8 NSs per milliliter). The nanoparticles have r1 relaxivities more than three times larger than those of conventional T1 contrast agents, requiring less concentration of Gd 3+ to observe an equivalent signal enhancement in T1 -weighted MR images. Furthermore, Gd 2 O 3 -MS NS nanoparticles have r2 relaxivities comparable to those of existing T2 contrast agents, observed in agarose phantoms. This highly unusual combination of simultaneous T1 and T2 contrast allows for MRI enhancement through different approaches. As a rudimentary example, we demonstrate T1 / T2 ratio MR images with sixfold contrast signal enhancement relative to its T1 MRI and induced temperature increases of 20 to 55 °C under clinical illumination conditions. These nanoparticles facilitate MRI-guided PTT while providing real-time temperature feedback through thermal MRI mapping.
Recent emphasis has focused on the development of rationally designed polymer-based micelle carriers for drug delivery. The current work tests the hypothesis that target specificity can be enhanced by micelles with cancer-specific ligands. In particular, we describe the synthesis and characterization of a new gadolinium texaphyrin (Gd-Tx) complex encapsulated in an IVECT micellar system, stabilized through Fe(III) cross-linking and targeted with multiple copies of a specific ligand for the melanocortin 1 receptor (MC1R), which has been evaluated as a cell-surface marker for melanoma. On the basis of comparative MRI experiments, we have been able to demonstrate that these Gd-Tx micelles are able to target MC1R-expressing xenograft tumors in vitro and in vivo more effectively than various control systems, including untargeted or un-cross-linked Gd-Tx micelles. Taken in concert, the findings reported herein support the conclusion that appropriately designed micelles are able to deliver contrast agent payloads to tumors expressing the MC1R.
Background: Magnetic resonance spectroscopic imaging (MRSI) offers valuable metabolic information for assessing brain tumor progression and therapeutic response, but its performance in rodent models is often hindered by the low signal-to-noise ratio (SNR) and spatially heterogeneous spectral quality, particularly in peripheral voxels. These issues reduce the number of usable spectra available for quantitative and classifier-based analyses. To address this, we implemented a multi-voxel MRSI-semiLASER sequence—widely recommended in clinical practice—on a 7T Bruker Biospec system running ParaVision 5.1 to improve spectral homogeneity in mouse brain tumor studies. Results: Compared with the vendor CSI-PRESS sequence, MRSI-semiLASER produced more uniform spectra across the grid and achieved up to a 1.2-fold SNR increase in murine glioma, enabling a 20% reduction in slice thickness without compromising spectral quality. Importantly, the sequence produced a substantial gain in the proportion of spectra amenable to analysis, particularly in outer grid voxels that frequently fail with CSI-PRESS. The implemented MRSI-semiLASER sequence and instructions are openly available to the community. Conclusions: MRSI-semiLASER improves spectral homogeneity, increases the proportion of usable spectra, and supports higher spatial detail. These technical improvements may enhance data yield per subject and may facilitate future applications such as more robust pattern recognition workflows and greater data efficiency in longitudinal studies, although such aspects were not evaluated here.